These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 26785951)

  • 1. Quality registries: exciting opportunities.
    Ludvigsson JF
    J Intern Med; 2016 Feb; 279(2):130-1. PubMed ID: 26785951
    [No Abstract]   [Full Text] [Related]  

  • 2. Asthma phenotyping: noninvasive biomarkers suitable for bedside science are the next step to implement precision medicine.
    Dahlén SE
    J Intern Med; 2016 Feb; 279(2):205-7. PubMed ID: 26785954
    [No Abstract]   [Full Text] [Related]  

  • 3. Asthma phenotyping: a necessity for improved therapeutic precision and new targeted therapies.
    Chung KF
    J Intern Med; 2016 Feb; 279(2):192-204. PubMed ID: 26076339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [State of play of French data collections in the field of rare diseases].
    Aymé S
    Med Sci (Paris); 2018 May; 34 Hors série n°1():22-25. PubMed ID: 29911549
    [No Abstract]   [Full Text] [Related]  

  • 5. Reslizumab (Cinqair) for severe eosinophilic asthma.
    Med Lett Drugs Ther; 2016 Jun; 58(1497):81-2. PubMed ID: 27305070
    [No Abstract]   [Full Text] [Related]  

  • 6. Need for a roadmap for development of a coordinated national registry programme.
    Wilkins S; Best RL; Evans SM
    Intern Med J; 2015 Nov; 45(11):1189-92. PubMed ID: 26352196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The eXpeRience registry: the 'real-world' effectiveness of omalizumab in allergic asthma.
    Braunstahl GJ; Chen CW; Maykut R; Georgiou P; Peachey G; Bruce J
    Respir Med; 2013 Aug; 107(8):1141-51. PubMed ID: 23721684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How can the research potential of the clinical quality databases be maximized? The Danish experience.
    Nørgaard M; Johnsen SP
    J Intern Med; 2016 Feb; 279(2):132-40. PubMed ID: 26785952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strict adherence rules to obtain monoclonal therapy might cost lives.
    Green RH; Shaw D
    Lancet Respir Med; 2017 Sep; 5(9):678-679. PubMed ID: 28666608
    [No Abstract]   [Full Text] [Related]  

  • 10. Pediatric asthma: guidelines-based care, omalizumab, and other potential biologic agents.
    Huffaker MF; Phipatanakul W
    Immunol Allergy Clin North Am; 2015 Feb; 35(1):129-44. PubMed ID: 25459581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dupilumab (Dupixent) for Asthma.
    Barry K; Gorelik D
    Am Fam Physician; 2020 Feb; 101(4):244-245. PubMed ID: 32053330
    [No Abstract]   [Full Text] [Related]  

  • 12. Data Quality in Rare Diseases Registries.
    Kodra Y; Posada de la Paz M; Coi A; Santoro M; Bianchi F; Ahmed F; Rubinstein YR; Weinbach J; Taruscio D
    Adv Exp Med Biol; 2017; 1031():149-164. PubMed ID: 29214570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Arthroplasty registries and their contribution to the safety of patient care in joint replacement].
    Heinz BC
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2009 Jun; 52(6):589-93. PubMed ID: 19412594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular phenotyping and biomarker development: are we on our way towards targeted therapy for severe asthma?
    De Ferrari L; Chiappori A; Bagnasco D; Riccio AM; Passalacqua G; Canonica GW
    Expert Rev Respir Med; 2016; 10(1):29-38. PubMed ID: 26566089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benralizumab for the treatment of asthma.
    Matera MG; Rogliani P; Calzetta L; Canonica GW; Cazzola M
    Drugs Today (Barc); 2017 Dec; 53(12):633-645. PubMed ID: 29517082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Severe refractory eosinophilic asthma].
    Jäger-Becker D
    MMW Fortschr Med; 2016 Feb; 158(3):67. PubMed ID: 27119709
    [No Abstract]   [Full Text] [Related]  

  • 17. [Targeted asthma therapies: confirmations, hopes, and disappointments].
    Schleich F; Louis R
    Rev Med Liege; 2012; 67 Spec No():14-21. PubMed ID: 22690481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Severe asthma, IgE and anti-IgE: from sceptical waiting to factual learning].
    Blanc FX
    Rev Mal Respir; 2005 Dec; 22(6 Pt 1):925-7. PubMed ID: 16220115
    [No Abstract]   [Full Text] [Related]  

  • 19. Disconnect for Tezepelumab on Exacerbations, Symptoms, and Quality of Life in Type 2 Low Asthma.
    Lipworth B; Chan R
    Am J Respir Crit Care Med; 2023 Jul; 208(2):211. PubMed ID: 37279364
    [No Abstract]   [Full Text] [Related]  

  • 20. [Omalizumab in severe asthma--case report].
    Gawlewicz-Mroczka A; Nizankowska-Mogilnicka E
    Pol Arch Med Wewn; 2006 Aug; 116(2):766-70. PubMed ID: 17424922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.